HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Co. Ltd.

www.eisai.com

Latest From Eisai Co. Ltd.

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

Biogen Aducanumab BLA Plan Is In Line With US FDA Neurology Division Precedent

Biogen and Eisai's surprise decision to advance Alzheimer’s antibody despite mixed clinical results could follow a similar path as pioneering neurodegenerative therapies Xenazine and Rilutek, or more recent Parkinson’s drug Nourianz – or could end with suspended development, like Kyndrisa.
Neurology Drug Approval Standards

Beyond Next Aims To Boost Bioventures Over Japan Hurdles

Set up to support the development of bioventures in Japan, Tokyo’s Beyond Next Ventures sees itself as a broad-benefit accelerator able to work with a wide range of partners to help discover and develop life science innovation, in an environment that still presents challenges.

Japan Financing

Interview: Vivoryon Raises €43m After Alzheimer's Revival

New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.

Financing Companies
See All

Company Information

UsernamePublicRestriction

Register